Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20400230 | 0.79 | KDM4E (0.40) | KDM4ECYP1A2 | |
| SCHEMBL24121647 | 0.79 | CYP1A2 (0.31) | KDM4ECYP1A2 | |
| SCHEMBL21076960 | 0.76 | CYP1A2 (0.40) | CYP1A2 | |
| SCHEMBL5652378 | 0.75 | CYP1A2 (0.56) | CYP1A2 | |
| SCHEMBL24030294 | 0.70 | MEN1 (0.36) | KDM4EGPR139 | |
| SCHEMBL26254235 | 0.70 | CHRM4 (0.36) | CYP1A2CYP2A6GPR139 | |
| SCHEMBL25516750 | 0.68 | CYP2A6 (0.32) | KDM4ECYP1A2CYP2E1CYP2A6 | |
| SCHEMBL15871362 | 0.65 | GPR139 (0.33) | GPR139 | |
| SCHEMBL24834551 | 0.65 | TGFBR1 (0.35) | GPR139 | |
| SCHEMBL22622075 | 0.65 | GPR139 (0.44) | GPR139 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023083285-A1 | SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2023-05-19 | — | — | WO | disclosed |
| EP-3317285-B1 | CHIRAL DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | TURNING POINT THERAPEUTICS INC (US) | 2021-01-27 | — | — | EP | disclosed |
| EP-3636649-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | Turning Point Therapeutics, Inc. (US) | 2020-04-15 | — | — | EP | disclosed |
| EP-3636650-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | Turning Point Therapeutics, Inc. (US) | 2020-04-15 | — | — | EP | disclosed |
| EP-3097107-B1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | TP THERAPEUTICS INC (US) | 2019-04-17 | — | — | EP | disclosed |
| US-20170334929-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | Turning Point Therapeutics, Inc. | 2017-11-23 | — | — | US | disclosed |
| US-9714258-B2 | Diaryl macrocycles as modulators of protein kinases | TP THERAPEUTICS, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| US-20170002023-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | TP THERAPEUTICS, INC. (US) | 2017-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334929-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | MAP3K20, LCK, MAP3K1 | KDM4E 1402/4885CYP1A2 4482/4885CYP2E1 4462/4885 |
| US-20170002023-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | MAP3K20, LCK, MAP3K1 | KDM4E 1402/4885CYP1A2 4482/4885CYP2E1 4462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.